Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Leases: 2022-2024

Historic Operating Leases for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $937,000.

  • Corvus Pharmaceuticals' Operating Leases rose 78.53% to $632,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $632,000, marking a year-over-year increase of 78.53%. This contributed to the annual value of $937,000 for FY2024, which is 31.80% down from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Operating Leases of $937,000 as of FY2024, which was down 31.80% from $1.4 million recorded in FY2023.
  • Over the past 5 years, Corvus Pharmaceuticals' Operating Leases peaked at $1.4 million during FY2023, and registered a low of $937,000 during FY2024.
  • For the 3-year period, Corvus Pharmaceuticals' Operating Leases averaged around $1.2 million, with its median value being $1.4 million (2022).
  • Its Operating Leases has fluctuated over the past 5 years, first rose by 0.07% in 2023, then tumbled by 31.80% in 2024.
  • Over the past 3 years, Corvus Pharmaceuticals' Operating Leases (Yearly) stood at $1.4 million in 2022, then grew by 0.07% to $1.4 million in 2023, then slumped by 31.80% to $937,000 in 2024.